Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of glasdegib versus placebo with intensive chemotherapy or azacitidine in previously untreated acute myeloid leukemia
MOH_2018-10-28_001899Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of glasdegib in acute myeloid leukemia (AML) (4 arms), sponsored by Pfizer. Started Oct 2018; status: active, not recruiting.
02
Drugs
glasdegib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on MOH_2018-10-28_001899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-10-28_001899.